Tsz Kin Lo

Dr. Tsz Kin Lo


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in Genes
Verified
Journal Article
Open access
PDF file
PSPo Lam So
Po Lam So
Shuk Yi Annie HuiShuk Yi Annie Hui
Shuk Yi Annie Hui
TMTeresa Wei Ling Ma
Teresa Wei Ling Ma
WSWendy Shu
Wendy Shu
PHPui Wah Hui
Pui Wah Hui
WLWing-cheong LEUNG
Wing-cheong LEUNG
With the advancements in prenatal diagnostics, genome sequencing is now incorporated into clinical use to maximize the diagnostic yield following uninformative conventional tests (karyotype and chromosomal microarray analysis). Hong Kong started publicly funded prenatal genomic sequencing as a sequential test in the investigation of fetal structural anomalies in April 2021. The objective of the study was to evaluate the clinical performance and usefulness of this new service over one year. We established a web-based multidisciplinary team to facilitate case selection among the expert members. We retrospectively analyzed the fetal phenotypes, test results, turnaround time and clinical impact in the first 15 whole exome sequencing and 14 whole genome sequencing. Overall, the molecular diagnostic rate was 37.9% (11/29). De novo autosomal dominant disorders accounted for 72.7% (8/11), inherited autosomal recessive disorders for 18.2% (2/11), and inherited X-linked disorders for 9.1% (1/11). The median turnaround time for ongoing pregnancy was 19.5 days (range, 13–31 days). Our study showed an overall clinical impact of 55.2% (16/29), which influenced reproductive decision-making in four cases, guided perinatal management in two cases and helped future family planning in ten cases. In conclusion, our findings support the important role of genome sequencing services in the prenatal diagnosis of fetal structural anomalies in a population setting. It is important to adopt a multidisciplinary team approach to support the comprehensive genetic service.

1 November 2021 in Computers in Biology and Medicine
Verified
Journal Article
Open access
AKAki Koivu
Aki Koivu
MSMikko Sairanen
Mikko Sairanen
AAAntti Airola
Antti Airola
TPTapio Pahikkala
Tapio Pahikkala
WLWing-cheong LEUNG
Wing-cheong LEUNG
DSDaljit Singh Sahota
Daljit Singh Sahota
Currently, popular methods for prenatal risk assessment of fetal aneuploidies are based on multivariate probabilistic modelling, that are built on decades of scientific research and large-scale multi-center clinical studies. These static models that are deployed to screening labs are rarely updated or adapted to local population characteristics. In this article, we propose an adaptive risk prediction system or ARPS, which considers these changing characteristics and automatically deploys updated risk models. 8 years of real-life Down syndrome screening data was used to firstly develop a distribution shift detection method that captures significant changes in the patient population and secondly a probabilistic risk modelling system that adapts to new data when these changes are detected. Various candidate systems that utilize transfer -and incremental learning that implement different levels of plasticity were tested. Distribution shift detection using a windowed approach provides a computationally less expensive alternative to fitting models at every data block step while not sacrificing performance. This was possible when utilizing transfer learning. Deploying an ARPS to a lab requires careful consideration of the parameters regarding the distribution shift detection and model updating, as they are affected by lab throughput and the incidence of the screened rare disorder. When this is done, ARPS could be also utilized for other population screening problems. We demonstrate with a large real-life dataset that our best performing novel Incremental-Learning-Population-to-Population-Transfer-Learning design can achieve on par prediction performance without human intervention, when compared to a deployed risk screening algorithm that has been manually updated over several years.

16 July 2024 in Maternal-Fetal Medicine
Verified
Journal Article
Open access
HLHiu Yu Hillary Leung
Hiu Yu Hillary Leung
TMTeresa Wl Ma
Teresa Wl Ma
FYFlorrie Ny Yu
Florrie Ny Yu
MKMeliza Cw Kong
Meliza Cw Kong
TLTsz Kin Lo
Tsz Kin Lo
LPLiona C. Poon
Liona C. Poon
Objective: To report the clinical maternal and fetal outcomes of pregnant women with coronavirus disease 2019 (COVID-19), along with any associated pregnancy complications, in Hong Kong, China, and to assess the impact of COVID-19 vaccination on these outcomes. Methods: This prospective registry-based observational study included pregnant women who were recruited through convenient sampling and had a laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection with a cycle threshold (Ct) value result available on admission to eight local hospitals in Hong Kong, China. Data on clinical symptoms, laboratory results, medical treatments, delivery timing and mode, and pregnancy complications were extracted from the Hospital Authority’s electronic medical record system. Maternal, fetal, and pregnancy outcomes were compared between unvaccinated pregnant women with COVID-19 and those who had received at least one dose of COVID-19 vaccine before diagnosis. Nonparametric continuous variables and categorical variables were analyzed using the Mann-Whitney U test and the Pearson’s chi-squared test respectively. A P value less than 0.05 was considered statistically significant. Results: A total of 164 pregnant women were included, of whom 78 (47.56%) were nulliparous. COVID-19 was diagnosed before 28 weeks’ gestation in 30 (18.29%), while 134 (81.71%) were diagnosed at or after 28 weeks’ gestation. Sixty-two (37.80%) women received at least one dose of COVID-19 vaccine. There were no significant differences between vaccinated and unvaccinated groups in the time interval between COVID-19 diagnosis and delivery, the Ct value, and the gestational age at infection onset or delivery (P > 0.05). The majority of women were symptomatic at diagnosis regardless of vaccination status (55 (88.71%) in vaccinated group vs. 78 (76.47%) in unvaccinated group (P = 0.052). Symptoms did not significantly differ between groups except for cough (62.90% vs. 47.06%, P = 0.049). The overall rate of severe COVID-19 in pregnant women was low. In total, 5 (3.05%) patients experienced severe COVID-19, with vaccinated patients more likely to receive low molecular weight heparin (LMWH) as part of their treatment (62.90% vs. 42.16%, P = 0.010). Ninety-two (56.10%) women had a spontaneous vaginal delivery, 7 (4.27%) had an instrumental delivery, and 44 (26.83%) and 21 (12.80%) underwent emergency and elective cesarean sections respectively. For fetal outcomes, 14 (8.48%) babies were born preterm and four (2.65% of nonpreterm babies, n = 151) had low birthweight. The median birthweight percentile was 52.18th. There were no statistically significant differences in pregnancy complications or fetal outcomes between vaccinated and unvaccinated groups. Conclusion: The overall rate of severe COVID-19 in pregnant women was low. COVID-19 vaccination did not significantly impact maternal outcomes, except for the use of LMWH. Additionally, the study found no significant differences in fetal outcomes and pregnancy complications between vaccinated and unvaccinated individuals.

3 June 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
YZYU ZHENG
YU ZHENG
MSMengmeng SHI
Mengmeng SHI
YZYilin Zhao
Yilin Zhao
CCCheuk Yan Chung
Cheuk Yan Chung
MCMatthew Hoi Kin Chau
Matthew Hoi Kin Chau
YCYe Cao
Ye Cao
Background/Objectives: Recessive titinopathies caused by biallelic TTN truncating variants (TTNtvs) present a clinically heterogeneous spectrum from fetal demise to late-onset slowly progressive distal muscular dystrophy. Prognostic counseling is challenging due to the vast size of the TTN gene, complex splicing patterns, and differential expression throughout developmental stages and tissues. This paper aims to delineate the regional genotype patterns and clinical characteristics of recessive titinopathies described from the prenatal period onwards to inform genotype–phenotype associations and genetic counseling. Methods: We analyzed clinical and genetic data from a prenatal-onset cohort with biallelic TTNtvs from both previously reported cases and novel cases from our center. To characterize the regional distribution of biallelic variants within this specific cohort, a two-dimensional scatter plot was utilized to map variants onto 10 biological regions (R1–R10) and 55 analytical units (U1–U55). We also performed Fisher’s exact tests on the subset of 50 cases with confirmed survival records to evaluate statistically significant associations between biallelic regional or percent spliced-in (PSI) thresholds combinations and severe clinical endpoints (intrauterine demise or death before 5 years). Results: A total of 96 prenatal cases from 76 unrelated families were analyzed. Decreased fetal movement was the most commonly reported symptom, observed in 81.3% (78/96) of cases, which was followed by arthrogryposis in 45.8% (44/96) and amniotic fluid volume abnormalities in 35.4% (34/96). Additionally, of the 95 cases with known pregnancy outcomes, 25.3% (24/95) resulted in termination and 11.6% (11/95) resulted in intrauterine demise (IUD), while 63.2% (60/95) reached birth with over 16.7% (10/60) being preterm. Among 60 live-born infants, severe postnatal morbidity was high: 45.0% (27/60) experienced respiratory failure, and 33.3% (20/60) died before the age of five. In this cohort, 84.4% (81/96) of cases possessed at least one TTNtv in either the metatranscript-only or A-band regions. The most common biallelic changes involved TTNtvs in both the A-band and metatranscript-only regions, accounting for 35.4% (34/96) of cases, followed by metatranscript-only combined with I-band variants at 16.7% (16/96), regardless of the PSI score of exons. Overall, 83.3% (80/96) had ≥1 variant on low-PSI (90%) exons were significantly associated with severe outcomes (intrauterine demise or death before 5 years; exact p = 0.015), whereas the metatranscript-only plus I-band combination conferred a significantly lower risk of lethality before 5 years of age (exact p = 0.001). Conclusions: Our findings add to the accumulating evidence that TTNtvs on low PSl exons or metatranscript-only regions are frequently observed among reported prenatal-onset recessive titinopathy. Health surveillance for heterozygous carriers among family members is warranted due to the substantial risk for adult-onset dilated cardiomyopathy and peripartum cardiomyopathy.